CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

16 Jan 20264 min read0 viewsINTERVENTIONAL Trial

GIST

RECRUITING · INTERVENTIONAL · TREATMENT study · Relapsed/Refractory Acute Myeloid Leukemia (AML) · Phase 1 · Enrollment 60 · Sponsor: Cullinan Therapeutics Inc.

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Oncology on 16 Jan 2026. The item focuses on CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). Open the detail page to review the full original feed content.